DDX39B-AS1: A Promising Drug Target and Biomarker for Chronic Myeloid Leukemia

Target Name: DDX39B-AS1

NCBI ID: G106478957

DDX39B-AS1

Other Name(s): DDX39B antisense RNA 1 | DDX39B antisense RNA 1, transcript variant 1 | DDX39B-AS1 variant 1

DDX39B-AS1: A Promising Drug Target and Biomarker for Chronic Myeloid Leukemia

Introduction

Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow, where white blood cells called leukemia cells overgrow. This condition can be treated with different drugs, but the treatment often comes with a high risk of side effects. Researchers and pharmaceutical companies are always looking for new treatments and biomarkers to improve the treatment outcomes of CML patients. In this article, we will discuss DDX39B-AS1, a drug target and biomarker for CML.

Drug Target: DDX39B

DDX39B (Dasodactinib) is an oral inhibitor of the tyrosine kinase inhibitor ABL kinase, which is a protein that regulates the growth and survival of leukemia cells. ABL kinase is a common target for tyrosine inhibitor kinases, and inhibiting it can lead to the death of leukemia cells. DDX39B works by inhibiting the activity of ABL kinase, leading to the inhibition of leukemia cell growth and proliferation.

DDX39B-AS1 is a modified form of DDX39B that is designed to be a better carrier for the treatment of CML. It is made by genetic engineering technology, changing the amino acid sequence of DDX39B to AS1, allowing it to better cross the blood brain barrier, thereby improving the therapeutic effect of drugs in CML patients.

Biomarker

DDX39B-AS1 can be used as a biomarker for CML to detect disease progression and treatment efficacy. By testing levels of DDX39B-AS1, doctors can determine how CML patients are responding to treatment and can alter treatment options. DDX39B-AS1 levels can also be used as a monitoring biomarker for CML. By monitoring its levels, the treatment effect of patients can be evaluated and disease progression can be predicted.

and traditional healing

Compared with traditional treatment options, DDX39B-AS1 has the following advantages in treating CML. First, DDX39B-AS1 can cross the blood-brain barrier and treat central nervous system leukemia. Traditional treatment options have difficulty crossing the blood-brain barrier, so DDX39B-AS1 is an effective treatment option for patients with central nervous system leukemia. Secondly, DDX39B-AS1 can inhibit ABL kinase, which is one of the characteristics of CML, so DDX39B-AS1 can treat CML. Finally, DDX39B-AS1 is an oral drug that can better improve patients' daily habits.

Conclusion

DDX39B-AS1 is an effective drug target and biomarker for CML. It can inhibit ABL kinase, treat CML and serve as a biomarker for CML. By inhibiting ABL kinase, DDX39B-AS1 can treat central nervous system leukemia and is an effective treatment option. Compared with other traditional treatment options, DDX39B-AS1 has better therapeutic effects and fewer side effects. Therefore, DDX39B-AS1 is a promising drug target and biomarker for CML.

Protein Name: DDX39B Antisense RNA 1

The "DDX39B-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX39B-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets